Related Experiment Video
Updated: Aug 4, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
CD-20 expression in post-transplant lymphoproliferative disorders: treatment with rituximab
J J Ifthikharuddin1, L A Mieles, J D Rosenblatt
1Department of Hematology-Oncology, University of Rochester, Strong Memorial Hospital, Rochester, New York 14642, USA. j.j_ifthikharuddin@urmc.rochester.edu
American Journal of Hematology
|September 21, 2000
Abstract:
B-cell lymphoproliferative disorders are rare but serious complications of solid organ and bone marrow transplantation. We report that these tumors frequently express the CD-20 antigen, and immunotherapy directed at this antigen may be a well-tolerated and effective treatment.
